Dinesh Paliwal joins Board of Directors at Bristol-Myers Squibb

He will serve as a member of the Committee on Directors and Corporate Governance

Bristol-Myers Squibb has elected Dinesh Paliwal to its Board of Directors. He will serve as a member of the Committee on Directors and Corporate Governance.

Paliwal is currently the Chairman, President and Chief Executive of Harman International Industries, a provider of audio and infotainment systems for the automotive, consumer and professional markets, a position he has held since 2008. He was Harman’s President and Chief Executive from 2007 to 2008.

Prior to joining Harman, Paliwal spent 22 years with ABB Group, where he last held the dual role of President, Global Markets and Technologies of ABB Ltd and Chairman and Chief Executive of ABB North America. Paliwal serves on the board of ADT Corporation and has previously served as Chairman of the US National Foreign Trade Council.

You may also like

Manufacturing

Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities

Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Finance

Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb

The biotech company focuses on developing new drugs for fibrotic and other inflammatory diseases
Manufacturing

Bristol-Myers Squibb and Catalent close Italian manufacturing deal

Former BMS manufacturing and packaging facility in Anagni is now under Catalent ownership
Design & Build

Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy

Facility in Anagni is equipped with oral solid, biologics, and sterile product manufacturing and packaging capabilities
Research & Development

Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies

Biocartis Group has signed a collaboration agreement with Bristol-Myers Squibb to register and use the Idylla MSI test in connection with immuno-oncology therapies
Media

BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants

Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Finance

Bristol-Myers Squibb to merge with Celgene in multimillion deal

Transaction will see a combined pharmaceutical company in pole position within the immuno-oncology and the treatment of blood cancers market
Subscribe now